Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function-Reference-Cited by-同舟云学术

Long-term therapy with non-steroidal anti-inflammatory drugs for axial spondyloarthritis: focus on changes in liver function

Published:2021-05-22 Issue:3 Volume: Page:152-157
ISSN:1682-8658
Container-title:Experimental and Clinical Gastroenterology
language:
Short-container-title:jour

Author:

Rebrov A. P.¹^ORCID,Aparkina A. V.¹,Kchondkaryan E. V.¹

Affiliation:

1. Saratov State Medical University named after V. I. Razumovsky

Abstract

The purpose of the study is to analyze the state of liver function in patients with spondyloarthritis taking non-steroidal anti-inflammatory drugs continuously for 24 months. Materials and methods of the study include 198 patients with spondyloarthritis. The prospective study involved 36 patients with spondyloarthritis who took non-steroidal anti-inflammatory drugs (NSAIDs) prescribed by a physician in the community for 24 months. The level of liver enzymes in blood serum at admission and in dynamics was studied. The increase of liver enzymes was detected in 12 (6.06%) of 198 patients with spondyloarthritis. Among them 6 (50%) patients took methotrexate, 1 (8.33%) - genetically engineered drug, 2 (16.67%) patients-sulfasalazine and 3 (25%) - nonsteroidal anti - inflammatory drugs. 19.4% of patients were registered with a periodic increase of transaminase levels on the background of NSAIDs for the last 24 months. At the same time, no cases of acute liver damage or progressive deterioration of liver function requiring discontinuation of therapy were recorded during the entire follow-up period.

Publisher

LLC Global Media Technology

Subject

General Medicine

Reference21 articles.

1. van der Heijden D., Ramiro S., Landewé R. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017, vol. 76, pp. 978-991.

2. Gaidukova I.Z., Rebrov A. P., Korotaeva T. V., et al. Remission in axial spondyloarthritis: Definition and evaluation tools (recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization “The Association of Rheumatology of Russia”). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice, 2018, vol. 56, no.1, pp. 10-14 (In Russ.) doi: 10.14412/1995-4484-2018-10-14@@ Gaidukova I. Z., Rebrov A. P., Korotaeva T. V. i dr. Remissiya pri aksial'nykh spondiloartritakh - opredelenie i instrumenty otsenki (rekomendatsii Ekspertnoi gruppy po izucheniyu spondiloartritov pri Obshcherossiiskoi obshchestvennoi organizatsii «Assotsiatsiya revmatologov Rossii»). Nauchno-prakticheskaya revmatologiya. - 2018 - T. 56. - № 1. - S. 10-14.

3. R. J. Lories, F. P. Luyten, K. de Vlam. Progress in spondyloarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthr research & therapy. 2009, vol. 11, no. 2, pp. 221. doi:10.1186/ar2642.

4. D. Poddubnyy, D. van der Heijde. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012, vol. 38, no. 3, pp. 601-611.

5. Donati M., Conforti A., Lenti M. C., et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016, vol. 82, no. 1, pp. 238-248. doi: 10.1111/bcp.12938. Epub 2016 Apr 27.